UPB
Upstream Bio, Inc. NASDAQ Listed Oct 11, 2024$9.19
After hrs
$9.19
+0.00%
Mkt Cap $500.1M
52w Low $7.25
7.3% of range
52w High $33.68
50d MA $9.07
200d MA $18.86
P/E (TTM)
-3.5x
EV/EBITDA
-8.5x
P/B
1.5x
Debt/Equity
0.0x
ROE
-42.2%
P/FCF
-11.0x
RSI (14)
—
ATR (14)
—
Beta
1.83
50d MA
$9.07
200d MA
$18.86
Avg Volume
1.3M
About
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonar…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | BMO | -0.73 | -0.79 | -8.2% | 9.79 | -10.9% | -11.4% | -11.4% | -10.3% | -8.1% | -4.9% | — |
| Nov 5, 2025 | BMO | -0.78 | -0.63 | +19.2% | 23.97 | +0.1% | -1.3% | -1.3% | -4.2% | -2.0% | -0.8% | — |
| Aug 6, 2025 | BMO | -0.61 | -0.74 | -21.3% | 16.72 | +2.0% | -5.3% | -5.3% | -4.3% | -0.8% | +4.7% | — |
| May 6, 2025 | BMO | -0.49 | -0.51 | -4.1% | 8.21 | -0.7% | +4.5% | +4.5% | +7.7% | +7.4% | +15.7% | — |
| Mar 13, 2025 | BMO | -0.56 | -1.59 | -183.9% | 9.06 | +3.0% | +6.1% | +6.1% | +8.9% | -0.2% | -5.6% | — |
| Nov 7, 2024 | BMO | -0.54 | -6.96 | -1200.3% | 27.02 | +1.5% | -3.1% | -3.1% | -0.8% | -2.4% | -4.1% | — |
| Dec 31, 2023 | BMO | — | -0.14 | — | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | BMO | — | -0.09 | — | — | — | — | — | — | — | — | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 27 | Evercore ISI | Downgrade | Outperform → In Line | — | $9.79 | $8.72 | -10.9% | -11.4% | -10.3% | -8.1% | -4.9% | -3.0% |
Recent Filings
8-K
Unknown — 8-K Filing
Universal Proptech's at-the-market offering provides flexible capital-raising ability without immediate dilution, though investors should monitor for potential future share dilution if the company exercises this option.
Mar 26
8-K
Unknown — 8-K Filing
UPB's advancement to Phase 3 testing for verekitug signals potential commercialization progress, but investors should recognize clinical-stage companies carry high failure risk despite promising development milestones.
Mar 26
8-K · 7.01
! Medium
Upstream Bio, Inc. -- 8-K 7.01: Regulation FD Disclosure
Upstream Bio presented Phase 2 VALIANT trial data for verekitug in severe asthma, disclosing preliminary efficacy results that will likely influence investor sentiment toward the clinical program's viability and commercial potential.
Feb 11
8-K · 7.01
! Medium
Upstream Bio, Inc. -- 8-K 7.01: Regulation FD Disclosure
Upstream Bio disclosed material information via press release that investors should review in the exhibit for updates on company developments or business operations.
Feb 11
Data updated apr 27, 2026 6:54am
· Source: massive.com